Nkarta (NKTX) Share-based Compensation (2019 - 2026)
Nkarta's quarterly Share-based Compensation came in at $1.9 million in Q1 2026, down 33.03% year-on-year from $2.8 million in Q1 2025, and little changed quarter-over-quarter from $1.9 million in Q4 2025.
Nkarta has reported Share-based Compensation for 8 years, with the latest figure at $1.9 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 33.03% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (down 49.84% YoY), and the FY2025 full-year result was $8.6 million, down 48.84% from the prior year.
- Share-based Compensation for Q1 2026 stood at $1.9 million, roughly flat from $1.9 million in the prior quarter.
- The five-year high for Share-based Compensation was $4.7 million in Q1 2023, with the low at $1.8 million in Q3 2025.
- Average Share-based Compensation over 5 years is $3.6 million, with a median of $4.1 million recorded in 2024.
- Year-over-year, Share-based Compensation rose 22.41% in 2022 and sank 56.28% in 2025.
- Tracing NKTX's Share-based Compensation over 5 years: stood at $4.5 million in 2022, then slipped by 21.2% to $3.5 million in 2023, then grew by 10.88% to $3.9 million in 2024, then slumped by 51.23% to $1.9 million in 2025, then slipped by 0.05% to $1.9 million in 2026.
- The last three Share-based Compensation figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.90 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | 1.90 Mn |
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Dec 31, 2024 | 3.89 Mn |
| Dec 31, 2024 | 3.89 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.37 Mn |
| Dec 31, 2023 | 3.51 Mn |
| Dec 31, 2023 | 3.51 Mn |
| Sep 30, 2023 | 4.29 Mn |
| Sep 30, 2023 | 4.29 Mn |
| Jun 30, 2023 | 4.65 Mn |
| Jun 30, 2023 | 4.65 Mn |
| Mar 31, 2023 | 4.75 Mn |
| Mar 31, 2023 | 4.75 Mn |
| Dec 31, 2022 | 4.46 Mn |
| Dec 31, 2022 | 4.46 Mn |
| Sep 30, 2022 | 4.39 Mn |
| Sep 30, 2022 | 4.39 Mn |
| Jun 30, 2022 | 3.91 Mn |
| Jun 30, 2022 | 3.91 Mn |
| Mar 31, 2022 | 4.10 Mn |
| Mar 31, 2022 | 4.10 Mn |
| Dec 31, 2021 | 3.73 Mn |
| Dec 31, 2021 | 3.73 Mn |
| Sep 30, 2021 | 3.69 Mn |
| Sep 30, 2021 | 3.69 Mn |
| Jun 30, 2021 | 3.69 Mn |
| Jun 30, 2021 | 3.69 Mn |
| Mar 31, 2021 | 3.35 Mn |
| Mar 31, 2021 | 3.35 Mn |
| Dec 31, 2020 | 4.09 Mn |
| Dec 31, 2020 | 4.09 Mn |
| Sep 30, 2020 | 1.61 Mn |
| Sep 30, 2020 | 1.61 Mn |
| Jun 30, 2020 | 566,000.00 |
| Jun 30, 2020 | 566,000.00 |
| Mar 31, 2020 | 482,000.00 |
| Mar 31, 2020 | 482,000.00 |
| Dec 31, 2019 | 565,000.00 |
| Dec 31, 2019 | 565,000.00 |
| Sep 30, 2019 | 227,000.00 |
| Sep 30, 2019 | 227,000.00 |
| Jun 30, 2019 | 100,000.00 |
| Jun 30, 2019 | 100,000.00 |